Halbe Breite 1000x667 LETYBO v24

Croma-Pharma receives marketing authorisation for Letybo® in a further 12 European markets

Croma (Croma-Pharma® GmbH) announced today that it has received marketing authorisation for Letybo®, the company’s botulinum toxin product, in 12 additional European markets. These include Belgium, Cyprus, Czech Republic, Denmark, Finland, Greece, Hungary, Luxembourg, Malta, Norway, Slovakia and Sweden. Letybo® will be launched in these countries in the coming weeks.

Si eres un profesional de la salud (HCP), por favor inicia sesión para ver información específica sobre nuestros productos.

Inicio de sesión

Registro

* campos obligatorios